AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MDByVictoria Werth, MDOctober 7th 2026Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.